OncoCyte (OCX) News Today $2.65 -0.07 (-2.57%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.64 -0.02 (-0.57%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period OncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying RecentlyFebruary 21 at 3:54 AM | msn.comOncocyte corp CFO buys $200,000 in stockFebruary 12, 2025 | msn.comAndrea S. James Buys 97,561 Shares of OncoCyte Co. (NASDAQ:OCX) StockFebruary 12, 2025 | insidertrades.comOncocyte corp's Patrick Smith acquires shares worth $2.2 millionFebruary 11, 2025 | msn.comBroadwood Partners acquires OncoCyte shares worth $9.24 millionFebruary 11, 2025 | msn.comOncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFebruary 11, 2025 | globenewswire.comOncocyte Prices $29.1 Million Equity OfferingFebruary 10, 2025 | globenewswire.comOncocyte corp investor Patrick Smith buys $1,839 in sharesFebruary 5, 2025 | msn.comInsider Stock Buying Reaches US$508.4k On OncoCyteJanuary 31, 2025 | finance.yahoo.comOncoCyte stock hits 52-week low at $1.92 amid market challengesJanuary 22, 2025 | msn.comInsider Buying: OncoCyte Co. (NASDAQ:OCX) Major Shareholder Purchases 5,669 Shares of StockJanuary 16, 2025 | insidertrades.comOncoCyte appoints Billings as consulting CMOJanuary 8, 2025 | markets.businessinsider.comOncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerJanuary 8, 2025 | globenewswire.comOncocyte Expands Market Opportunity for VitaGraft™ KidneyJanuary 6, 2025 | globenewswire.comInsider Buying: OncoCyte Co. (NASDAQ:OCX) Major Shareholder Purchases 90,219 Shares of StockDecember 31, 2024 | insidertrades.comAndrew Arno Purchases 12,500 Shares of OncoCyte Co. (NASDAQ:OCX) StockDecember 27, 2024 | insidertrades.comInsider Buying: OncoCyte Co. (NASDAQ:OCX) CFO Purchases 20,000 Shares of StockDecember 10, 2024 | insidertrades.comOncocyte to Participate in “J.P. Morgan Week” and Host Investor MeetingsDecember 9, 2024 | globenewswire.comOncoCyte Corporation: Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyDecember 5, 2024 | finanznachrichten.deOncoCyte announces publication of DetermaCNI assay dataDecember 4, 2024 | markets.businessinsider.comOncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyDecember 4, 2024 | globenewswire.comOncoCyte announces VitaGraft data published in journalDecember 4, 2024 | markets.businessinsider.comOncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study AffirmsDecember 2, 2024 | globenewswire.comOncoCyte Corp Reports Q3 2024 Earnings and Strategic UpdatesNovember 13, 2024 | markets.businessinsider.comOncoCyte’s Strategic Advances and Financial Prudence Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comOncoCyte Corporation (NASDAQ:OCX) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comOncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ...November 13, 2024 | uk.finance.yahoo.comOncoCyte Corporation (OCX) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comWhat to Expect from OncoCyte's EarningsNovember 11, 2024 | benzinga.comOncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12November 6, 2024 | globenewswire.comOncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.comStockNews.com assumed coverage on shares of OncoCyte in a research note on Saturday. They issued a "sell" rating on the stock.November 2, 2024 | marketbeat.comOncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.comStockNews.com initiated coverage on shares of OncoCyte in a research report on Sunday. They issued a "sell" rating for the company.October 27, 2024 | marketbeat.comOncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los AngelesOctober 16, 2024 | globenewswire.comOncoCyte’s Strategic Shift and Market Potential Justify Buy RatingOctober 16, 2024 | markets.businessinsider.comInsider Buying Slows, but Not for 7 These BuyersOctober 13, 2024 | 247wallst.comOncoCyte Corp (OCX) Q2 2024 Earnings Call Highlights: Strategic Advances Amidst Financial ChallengesOctober 9, 2024 | finance.yahoo.comOncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical TrialOctober 8, 2024 | markets.businessinsider.comOncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical TrialOctober 8, 2024 | globenewswire.comBroadwood Partners, L.P. Purchases 1,315,339 Shares of OncoCyte Co. (NASDAQ:OCX) StockOctober 7, 2024 | insidertrades.comOncoCyte Secures Funding Through Private Share SaleOctober 4, 2024 | finance.yahoo.comOncocyte Signs Leading Transplant Centers in US and GermanyOctober 2, 2024 | globenewswire.comOncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesOctober 2, 2024 | globenewswire.comBTIG Sticks to Their Hold Rating for OncoCyte (OCX)September 24, 2024 | markets.businessinsider.comPRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics TechnologyAugust 20, 2024 | finance.yahoo.comOncoCyte Corporation: Oncocyte's VitaGraft Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series StudyAugust 15, 2024 | finanznachrichten.deOncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series StudyAugust 12, 2024 | finance.yahoo.comOncocyte's VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series StudyAugust 12, 2024 | globenewswire.comOncoCyte Corporation (NASDAQ:OCX) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | msn.comOCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024August 10, 2024 | msn.comOncocyte Announces Successful GraftAssure(TM) Beta Launch and Q2 2024 ResultsAugust 10, 2024 | stockhouse.com Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Media Mentions By Week OCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCX News Sentiment▼0.000.60▲Average Medical News Sentiment OCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCX Articles This Week▼11▲OCX Articles Average Week Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Lyell Immunopharma News TuHURA Biosciences News Zentalis Pharmaceuticals News CARGO Therapeutics News Vaxart News Acrivon Therapeutics News Cidara Therapeutics News Alector News Aclaris Therapeutics News Inhibikase Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
